Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Leslie Beth Gordon, M.D.,Ph.D.


The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. R13AG071212 (GORDON, LESLIE B) Jan 15, 2021 - Dec 31, 2021
    The Progeria Research Foundation 10th International Scientific Workshop, Researching Possibilities, ExTENding Lives
    Role: Principal Investigator
  2. U01FD006886 (GORDON, LESLIE B) Sep 1, 2019 - Aug 31, 2021
    Progerin as a Biomarker for Hutchinson-Gilford Progeria Syndrome
    Role: Principal Investigator
  3. R13AG062031 (GORDON, LESLIE B) Sep 4, 2018 - Aug 31, 2019
    The Progeria Research Foundation 9th International Scientific Workshop Many Pathways, One Goal
    Role: Principal Investigator
  4. R13AG054149 (GORDON, LESLIE B) May 1, 2016 - Apr 30, 2017
    The Progeria Research Foundation 8th International Scientific Workshop Across the Table, Around the Globe
    Role: Principal Investigator
  5. R13AG046918 (GORDON, LESLIE B) Apr 1, 2013 - Mar 31, 2014
    PRF 11th Anniversary Workshop on Progeria - Hand in Hand: Basic and Clinica
    Role: Principal Investigator

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Lessel D, Rading K, Campbell SE, Thiele H, Altmüller J, Gordon LB, Kubisch C. A novel homozygous synonymous variant further expands the phenotypic spectrum of POLR3A-related pathologies. Am J Med Genet A. 2022 01; 188(1):216-223. PMID: 34611991.
    Citations:    Fields:    Translation:Humans
  2. Puttaraju M, Jackson M, Klein S, Shilo A, Bennett CF, Gordon L, Rigo F, Misteli T. Author Correction: Systematic screening identifies therapeutic antisense oligonucleotides for Hutchinson-Gilford progeria syndrome. Nat Med. 2021 Jul; 27(7):1309. PMID: 34075250.
    Citations:    Fields:    
  3. Koblan LW, Erdos MR, Gordon LB, Collins FS, Brown JD, Liu DR. Base editor treats progeria in mice. Nature. 2021 Jun 18. PMID: 34285403.
    Citations: 1     Fields:    
  4. Gordon LB, Tuminelli K, Andrés V, Campisi J, Kieran MW, Doucette L, Gordon AS. The progeria research foundation 10th international scientific workshop; researching possibilities, ExTENding lives - webinar version scientific summary. Aging (Albany NY). 2021 03 17; 13(6):9143-9151. PMID: 33735109.
    Citations:    Fields:    Translation:Humans
  5. Puttaraju M, Jackson M, Klein S, Shilo A, Bennett CF, Gordon L, Rigo F, Misteli T. Systematic screening identifies therapeutic antisense oligonucleotides for Hutchinson-Gilford progeria syndrome. Nat Med. 2021 03; 27(3):526-535. PMID: 33707772.
    Citations: 7     Fields:    Translation:HumansCells
  6. Erdos MR, Cabral WA, Tavarez UL, Cao K, Gvozdenovic-Jeremic J, Narisu N, Zerfas PM, Crumley S, Boku Y, Hanson G, Mourich DV, Kole R, Eckhaus MA, Gordon LB, Collins FS. A targeted antisense therapeutic approach for Hutchinson-Gilford progeria syndrome. Nat Med. 2021 03; 27(3):536-545. PMID: 33707773.
    Citations: 10     Fields:    Translation:HumansAnimals
  7. Koblan LW, Erdos MR, Wilson C, Cabral WA, Levy JM, Xiong ZM, Tavarez UL, Davison LM, Gete YG, Mao X, Newby GA, Doherty SP, Narisu N, Sheng Q, Krilow C, Lin CY, Gordon LB, Cao K, Collins FS, Brown JD, Liu DR. In vivo base editing rescues Hutchinson-Gilford progeria syndrome in mice. Nature. 2021 01; 589(7843):608-614. PMID: 33408413.
    Citations: 47     Fields:    Translation:HumansAnimalsCells
  8. Tsai A, Johnston PR, Gordon LB, Walters M, Kleinman M, Laor T. Skeletal maturation and long-bone growth patterns of patients with progeria: a retrospective study. Lancet Child Adolesc Health. 2020 04; 4(4):281-289. PMID: 32119840.
    Citations:    Fields:    Translation:Humans
  9. Lessel D, Ozel AB, Campbell SE, Saadi A, Arlt MF, McSweeney KM, Plaiasu V, Szakszon K, Szollos A, Rusu C, Rojas AJ, Lopez-Valdez J, Thiele H, Nürnberg P, Nickerson DA, Bamshad MJ, Li JZ, Kubisch C, Glover TW, Gordon LB. Analyses of LMNA-negative juvenile progeroid cases confirms biallelic POLR3A mutations in Wiedemann-Rautenstrauch-like syndrome and expands the phenotypic spectrum of PYCR1 mutations. Hum Genet. 2018 Dec; 137(11-12):921-939. PMID: 30450527.
    Citations: 9     Fields:    Translation:HumansCells
  10. Bassir SH, Chase I, Paster BJ, Gordon LB, Kleinman ME, Kieran MW, Kim DM, Sonis A. Microbiome at sites of gingival recession in children with Hutchinson-Gilford progeria syndrome. J Periodontol. 2018 06; 89(6):635-644. PMID: 29520806.
    Citations:    Fields:    Translation:Humans
  11. Gordon LB, Shappell H, Massaro J, D'Agostino RB, Brazier J, Campbell SE, Kleinman ME, Kieran MW. Association of Lonafarnib Treatment vs No Treatment With Mortality Rate in Patients With Hutchinson-Gilford Progeria Syndrome. JAMA. 2018 04 24; 319(16):1687-1695. PMID: 29710166.
    Citations: 55     Fields:    Translation:HumansCells
  12. Prakash A, Gordon LB, Kleinman ME, Gurary EB, Massaro J, D'Agostino R, Kieran MW, Gerhard-Herman M, Smoot L. Cardiac Abnormalities in Patients With Hutchinson-Gilford Progeria Syndrome. JAMA Cardiol. 2018 04 01; 3(4):326-334. PMID: 29466530.
    Citations: 22     Fields:    Translation:Humans
  13. DuBose AJ, Lichtenstein ST, Petrash NM, Erdos MR, Gordon LB, Collins FS. Everolimus rescues multiple cellular defects in laminopathy-patient fibroblasts. Proc Natl Acad Sci U S A. 2018 04 17; 115(16):4206-4211. PMID: 29581305.
    Citations: 20     Fields:    Translation:HumansCells
  14. Gordon LB, Campbell SE, Massaro JM, D'Agostino RB, Kleinman ME, Kieran MW, Moses MA. Survey of plasma proteins in children with progeria pre-therapy and on-therapy with lonafarnib. Pediatr Res. 2018 05; 83(5):982-992. PMID: 29342131.
    Citations: 7     Fields:    Translation:Humans
  15. Greer MM, Kleinman ME, Gordon LB, Massaro J, D'Agostino RB, Baltrusaitis K, Kieran MW, Gordon CM. Pubertal Progression in Female Adolescents with Progeria. J Pediatr Adolesc Gynecol. 2018 Jun; 31(3):238-241. PMID: 29258958.
    Citations: 3     Fields:    Translation:Humans
  16. Mantagos IS, Kleinman ME, Kieran MW, Gordon LB. Ophthalmologic Features of Progeria. Am J Ophthalmol. 2017 Oct; 182:126-132. PMID: 28756152.
    Citations:    Fields:    Translation:Humans
  17. Gabriel D, Shafry DD, Gordon LB, Djabali K. Intermittent treatment with farnesyltransferase inhibitor and sulforaphane improves cellular homeostasis in Hutchinson-Gilford progeria fibroblasts. Oncotarget. 2017 Sep 12; 8(39):64809-64826. PMID: 29029393.
    Citations: 18     Fields:    
  18. Gabriel D, Gordon LB, Djabali K. Temsirolimus Partially Rescues the Hutchinson-Gilford Progeria Cellular Phenotype. PLoS One. 2016; 11(12):e0168988. PMID: 28033363.
    Citations: 16     Fields:    Translation:HumansCells
  19. Bar DZ, Arlt MF, Brazier JF, Norris WE, Campbell SE, Chines P, Larrieu D, Jackson SP, Collins FS, Glover TW, Gordon LB. A novel somatic mutation achieves partial rescue in a child with Hutchinson-Gilford progeria syndrome. J Med Genet. 2017 03; 54(3):212-216. PMID: 27920058.
    Citations: 9     Fields:    Translation:HumansCells
  20. Rivera-Torres J, Calvo CJ, Llach A, Guzmán-Martínez G, Caballero R, González-Gómez C, Jiménez-Borreguero LJ, Guadix JA, Osorio FG, López-Otín C, Herraiz-Martínez A, Cabello N, Vallmitjana A, Benítez R, Gordon LB, Jalife J, Pérez-Pomares JM, Tamargo J, Delpón E, Hove-Madsen L, Filgueiras-Rama D, Andrés V. Cardiac electrical defects in progeroid mice and Hutchinson-Gilford progeria syndrome patients with nuclear lamina alterations. Proc Natl Acad Sci U S A. 2016 11 15; 113(46):E7250-E7259. PMID: 27799555.
    Citations: 24     Fields:    Translation:HumansAnimalsCells
  21. Gordon LB, Kleinman ME, Massaro J, D'Agostino RB, Shappell H, Gerhard-Herman M, Smoot LB, Gordon CM, Cleveland RH, Nazarian A, Snyder BD, Ullrich NJ, Silvera VM, Liang MG, Quinn N, Miller DT, Huh SY, Dowton AA, Littlefield K, Greer MM, Kieran MW. Clinical Trial of the Protein Farnesylation Inhibitors Lonafarnib, Pravastatin, and Zoledronic Acid in Children With Hutchinson-Gilford Progeria Syndrome. Circulation. 2016 Jul 12; 134(2):114-25. PMID: 27400896.
    Citations: 68     Fields:    Translation:HumansCellsCTClinical Trials
  22. Gordon LB, Kieran MW, Kleinman ME, Misteli T. The decision-making process and criteria in selecting candidate drugs for progeria clinical trials. EMBO Mol Med. 2016 07; 8(7):685-7. PMID: 27234439.
    Citations: 5     Fields:    Translation:Humans
  23. Ullrich NJ, Gordon LB. Hutchinson-Gilford progeria syndrome. Handb Clin Neurol. 2015; 132:249-64. PMID: 26564085.
    Citations: 40     Fields:    Translation:HumansAnimals
  24. Gabriel D, Roedl D, Gordon LB, Djabali K. Sulforaphane enhances progerin clearance in Hutchinson-Gilford progeria fibroblasts. Aging Cell. 2015 Feb; 14(1):78-91. PMID: 25510262.
    Citations: 38     Fields:    Translation:HumansCells
  25. Miyamoto MI, Djabali K, Gordon LB. Atherosclerosis in ancient humans, accelerated aging syndromes and normal aging: is lamin a protein a common link? Glob Heart. 2014 Jun; 9(2):211-8. PMID: 25667091.
    Citations: 5     Fields:    Translation:Humans
  26. Gordon LB, Massaro J, D'Agostino RB, Campbell SE, Brazier J, Brown WT, Kleinman ME, Kieran MW. Impact of farnesylation inhibitors on survival in Hutchinson-Gilford progeria syndrome. Circulation. 2014 Jul 01; 130(1):27-34. PMID: 24795390.
    Citations: 91     Fields:    Translation:HumansCells
  27. Gordon LB, Rothman FG, López-Otín C, Misteli T. Progeria: a paradigm for translational medicine. Cell. 2014 Jan 30; 156(3):400-7. PMID: 24485450.
    Citations: 107     Fields:    Translation:Humans
  28. Rork JF, Huang JT, Gordon LB, Kleinman M, Kieran MW, Liang MG. Initial cutaneous manifestations of Hutchinson-Gilford progeria syndrome. Pediatr Dermatol. 2014 Mar-Apr; 31(2):196-202. PMID: 24456199.
    Citations: 11     Fields:    Translation:Humans
  29. Ullrich NJ, Kieran MW, Miller DT, Gordon LB, Cho YJ, Silvera VM, Giobbie-Hurder A, Neuberg D, Kleinman ME. Neurologic features of Hutchinson-Gilford progeria syndrome after lonafarnib treatment. Neurology. 2013 Jul 30; 81(5):427-30. PMID: 23897869.
    Citations: 19     Fields:    Translation:HumansCTClinical Trials
  30. Silvera VM, Gordon LB, Orbach DB, Campbell SE, Machan JT, Ullrich NJ. Imaging characteristics of cerebrovascular arteriopathy and stroke in Hutchinson-Gilford progeria syndrome. AJNR Am J Neuroradiol. 2013 May; 34(5):1091-7. PMID: 23179651.
    Citations: 14     Fields:    Translation:Humans
  31. Gordon LB, Cao K, Collins FS. Progeria: translational insights from cell biology. J Cell Biol. 2012 Oct 01; 199(1):9-13. PMID: 23027899.
    Citations: 25     Fields:    Translation:HumansAnimals
  32. Gordon LB, Kleinman ME, Miller DT, Neuberg DS, Giobbie-Hurder A, Gerhard-Herman M, Smoot LB, Gordon CM, Cleveland R, Snyder BD, Fligor B, Bishop WR, Statkevich P, Regen A, Sonis A, Riley S, Ploski C, Correia A, Quinn N, Ullrich NJ, Nazarian A, Liang MG, Huh SY, Schwartzman A, Kieran MW. Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A. 2012 Oct 09; 109(41):16666-71. PMID: 23012407.
    Citations: 145     Fields:    Translation:HumansCTClinical Trials
  33. Cleveland RH, Gordon LB, Kleinman ME, Miller DT, Gordon CM, Snyder BD, Nazarian A, Giobbie-Hurder A, Neuberg D, Kieran MW. A prospective study of radiographic manifestations in Hutchinson-Gilford progeria syndrome. Pediatr Radiol. 2012 Sep; 42(9):1089-98. PMID: 22752073.
    Citations: 9     Fields:    Translation:Humans
  34. Wenzel V, Roedl D, Gabriel D, Gordon LB, Herlyn M, Schneider R, Ring J, Djabali K. Naïve adult stem cells from patients with Hutchinson-Gilford progeria syndrome express low levels of progerin in vivo. Biol Open. 2012 Jun 15; 1(6):516-26. PMID: 23213444.
    Citations: 15     Fields:    
  35. Ullrich NJ, Silvera VM, Campbell SE, Gordon LB. Craniofacial abnormalities in Hutchinson-Gilford progeria syndrome. AJNR Am J Neuroradiol. 2012 Sep; 33(8):1512-8. PMID: 22460337.
    Citations: 9     Fields:    Translation:Humans
  36. Gerhard-Herman M, Smoot LB, Wake N, Kieran MW, Kleinman ME, Miller DT, Schwartzman A, Giobbie-Hurder A, Neuberg D, Gordon LB. Mechanisms of premature vascular aging in children with Hutchinson-Gilford progeria syndrome. Hypertension. 2012 Jan; 59(1):92-7. PMID: 22083160.
    Citations: 55     Fields:    Translation:HumansCTClinical Trials
  37. Guardiani E, Zalewski C, Brewer C, Merideth M, Introne W, Smith AC, Gordon L, Gahl W, Kim HJ. Otologic and audiologic manifestations of Hutchinson-Gilford progeria syndrome. Laryngoscope. 2011 Oct; 121(10):2250-5. PMID: 21898437.
    Citations: 5     Fields:    Translation:Humans
  38. Harten IA, Zahr RS, Lemire JM, Machan JT, Moses MA, Doiron RJ, Curatolo AS, Rothman FG, Wight TN, Toole BP, Gordon LB. Age-dependent loss of MMP-3 in Hutchinson-Gilford progeria syndrome. J Gerontol A Biol Sci Med Sci. 2011 Nov; 66(11):1201-7. PMID: 21852285.
    Citations: 4     Fields:    Translation:HumansCells
  39. Gordon CM, Gordon LB, Snyder BD, Nazarian A, Quinn N, Huh S, Giobbie-Hurder A, Neuberg D, Cleveland R, Kleinman M, Miller DT, Kieran MW. Hutchinson-Gilford progeria is a skeletal dysplasia. J Bone Miner Res. 2011 Jul; 26(7):1670-9. PMID: 21445982.
    Citations: 35     Fields:    Translation:Humans
  40. Olive M, Harten I, Mitchell R, Beers JK, Djabali K, Cao K, Erdos MR, Blair C, Funke B, Smoot L, Gerhard-Herman M, Machan JT, Kutys R, Virmani R, Collins FS, Wight TN, Nabel EG, Gordon LB. Cardiovascular pathology in Hutchinson-Gilford progeria: correlation with the vascular pathology of aging. Arterioscler Thromb Vasc Biol. 2010 Nov; 30(11):2301-9. PMID: 20798379.
    Citations: 161     Fields:    Translation:Humans
  41. Marji J, O'Donoghue SI, McClintock D, Satagopam VP, Schneider R, Ratner D, Worman HJ, Gordon LB, Djabali K. Defective lamin A-Rb signaling in Hutchinson-Gilford Progeria Syndrome and reversal by farnesyltransferase inhibition. PLoS One. 2010 Jun 15; 5(6):e11132. PMID: 20559568.
    Citations: 35     Fields:    Translation:HumansAnimalsCells
  42. Domingo DL, Trujillo MI, Council SE, Merideth MA, Gordon LB, Wu T, Introne WJ, Gahl WA, Hart TC. Hutchinson-Gilford progeria syndrome: oral and craniofacial phenotypes. Oral Dis. 2009 Apr; 15(3):187-95. PMID: 19236595.
    Citations: 12     Fields:    Translation:Humans
  43. Gordon LB, Harling-Berg CJ, Rothman FG. Highlights of the 2007 Progeria Research Foundation scientific workshop: progress in translational science. J Gerontol A Biol Sci Med Sci. 2008 Aug; 63(8):777-87. PMID: 18772465.
    Citations: 11     Fields:    Translation:HumansAnimalsCells
  44. Bingham A, Mamyrova G, Rother KI, Oral E, Cochran E, Premkumar A, Kleiner D, James-Newton L, Targoff IN, Pandey JP, Carrick DM, Sebring N, O'Hanlon TP, Ruiz-Hidalgo M, Turner M, Gordon LB, Laborda J, Bauer SR, Blackshear PJ, Imundo L, Miller FW, Rider LG. Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity. Medicine (Baltimore). 2008 Mar; 87(2):70-86. PMID: 18344805.
    Citations: 48     Fields:    Translation:Humans
  45. Merideth MA, Gordon LB, Clauss S, Sachdev V, Smith AC, Perry MB, Brewer CC, Zalewski C, Kim HJ, Solomon B, Brooks BP, Gerber LH, Turner ML, Domingo DL, Hart TC, Graf J, Reynolds JC, Gropman A, Yanovski JA, Gerhard-Herman M, Collins FS, Nabel EG, Cannon RO, Gahl WA, Introne WJ. Phenotype and course of Hutchinson-Gilford progeria syndrome. N Engl J Med. 2008 Feb 07; 358(6):592-604. PMID: 18256394.
    Citations: 284     Fields:    Translation:Humans
  46. McClintock D, Ratner D, Lokuge M, Owens DM, Gordon LB, Collins FS, Djabali K. The mutant form of lamin A that causes Hutchinson-Gilford progeria is a biomarker of cellular aging in human skin. PLoS One. 2007 Dec 05; 2(12):e1269. PMID: 18060063.
    Citations: 158     Fields:    Translation:HumansCells
  47. Gordon LB, McCarten KM, Giobbie-Hurder A, Machan JT, Campbell SE, Berns SD, Kieran MW. Disease progression in Hutchinson-Gilford progeria syndrome: impact on growth and development. Pediatrics. 2007 Oct; 120(4):824-33. PMID: 17908770.
    Citations: 51     Fields:    Translation:Humans
  48. Kieran MW, Gordon L, Kleinman M. New approaches to progeria. Pediatrics. 2007 Oct; 120(4):834-41. PMID: 17908771.
    Citations: 42     Fields:    Translation:Humans
  49. Lemire JM, Patis C, Gordon LB, Sandy JD, Toole BP, Weiss AS. Aggrecan expression is substantially and abnormally upregulated in Hutchinson-Gilford Progeria Syndrome dermal fibroblasts. Mech Ageing Dev. 2006 Aug; 127(8):660-9. PMID: 16650460.
    Citations: 7     Fields:    Translation:HumansCells
  50. Varga R, Eriksson M, Erdos MR, Olive M, Harten I, Kolodgie F, Capell BC, Cheng J, Faddah D, Perkins S, Avallone H, San H, Qu X, Ganesh S, Gordon LB, Virmani R, Wight TN, Nabel EG, Collins FS. Progressive vascular smooth muscle cell defects in a mouse model of Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A. 2006 Feb 28; 103(9):3250-5. PMID: 16492728.
    Citations: 113     Fields:    Translation:HumansAnimalsCells
  51. McClintock D, Gordon LB, Djabali K. Hutchinson-Gilford progeria mutant lamin A primarily targets human vascular cells as detected by an anti-Lamin A G608G antibody. Proc Natl Acad Sci U S A. 2006 Feb 14; 103(7):2154-9. PMID: 16461887.
    Citations: 90     Fields:    Translation:HumansCells
  52. Scaffidi P, Gordon L, Misteli T. The cell nucleus and aging: tantalizing clues and hopeful promises. PLoS Biol. 2005 Nov; 3(11):e395. PMID: 16277559.
    Citations: 20     Fields:    Translation:HumansCells
  53. Capell BC, Erdos MR, Madigan JP, Fiordalisi JJ, Varga R, Conneely KN, Gordon LB, Der CJ, Cox AD, Collins FS. Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A. 2005 Sep 06; 102(36):12879-84. PMID: 16129833.
    Citations: 167     Fields:    Translation:HumansAnimalsCells
  54. Gordon LB, Harten IA, Patti ME, Lichtenstein AH. Reduced adiponectin and HDL cholesterol without elevated C-reactive protein: clues to the biology of premature atherosclerosis in Hutchinson-Gilford Progeria Syndrome. J Pediatr. 2005 Mar; 146(3):336-41. PMID: 15756215.
    Citations: 30     Fields:    Translation:Humans
  55. Goldman RD, Shumaker DK, Erdos MR, Eriksson M, Goldman AE, Gordon LB, Gruenbaum Y, Khuon S, Mendez M, Varga R, Collins FS. Accumulation of mutant lamin A causes progressive changes in nuclear architecture in Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A. 2004 Jun 15; 101(24):8963-8. PMID: 15184648.
    Citations: 465     Fields:    Translation:HumansCells
  56. Gordon LB, Harten IA, Calabro A, Sugumaran G, Csoka AB, Brown WT, Hascall V, Toole BP. Hyaluronan is not elevated in urine or serum in Hutchinson-Gilford Progeria Syndrome. Hum Genet. 2003 Jul; 113(2):178-87. PMID: 12728312.
    Citations: 11     Fields:    Translation:Humans
  57. Eriksson M, Brown WT, Gordon LB, Glynn MW, Singer J, Scott L, Erdos MR, Robbins CM, Moses TY, Berglund P, Dutra A, Pak E, Durkin S, Csoka AB, Boehnke M, Glover TW, Collins FS. Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature. 2003 May 15; 423(6937):293-8. PMID: 12714972.
    Citations: 806     Fields:    Translation:HumansCells
  58. Gordon LB, Nolan SC, Ksander BR, Knopf PM, Harling-Berg CJ. Normal cerebrospinal fluid suppresses the in vitro development of cytotoxic T cells: role of the brain microenvironment in CNS immune regulation. J Neuroimmunol. 1998 Aug 01; 88(1-2):77-84. PMID: 9688327.
    Citations: 12     Fields:    Translation:AnimalsCells
  59. Gordon LB, Nolan SC, Cserr HF, Knopf PM, Harling-Berg CJ. Growth of P511 mastocytoma cells in BALB/c mouse brain elicits CTL response without tumor elimination: a new tumor model for regional central nervous system immunity. J Immunol. 1997 Sep 01; 159(5):2399-408. PMID: 9278331.
    Citations: 10     Fields:    Translation:AnimalsCells
  60. Gordon LB, Knopf PM, Cserr HF. Ovalbumin is more immunogenic when introduced into brain or cerebrospinal fluid than into extracerebral sites. J Neuroimmunol. 1992 Sep; 40(1):81-7. PMID: 1517399.
    Citations: 18     Fields:    Translation:AnimalsPHPublic Health
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Gordon's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (339)
Co-Authors (26)
Similar People (60)
Same Department 
Physical Neighbors
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.